Protective effect of caffeine against high sugar-induced transcription of microRNAs and consequent gene silencing: A study using lenses of galactosemic mice

Shambhu D. Varma,1,2 Svitlana Kovtun1

1Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD; 2Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD

Purpose: Previous studies have shown that caffeine prevents the formation of cataracts induced by a high-galactose diet and consequent oxidative stress. The objective of this study was to investigate if this protective effect is reflected in the attenuation of the transcription of microRNAs (miRNAs) known to induce apoptosis and cell death by gene silencing.

Methods: Young CD-1 mice were fed either a normal laboratory diet or a diet containing 25% galactose with or without 1% caffeine. One week later, the animals were euthanized, and the lenses were isolated and promptly processed for RNA isolation and subsequent preparation of cDNAs by reverse transcriptase reaction. Mature miRNA (miR)-specific cDNAs were then quantified with PCR in a 96-well microRNA-specific cassette using an ABI7900HT PCR machine.

Results: As expected from previous studies, the lenses were positive for all 84 miRs corresponding to the miRNA probes present in the cassette wells. However, the levels of at least 19 miRs were significantly elevated in galactosemic lenses compared to those in the normal lenses. The majority are proapoptotic. Such elevation was inhibited by caffeine. This has been demonstrated for the first time.

Conclusions: Since aberrant elevation of miRNAs silences various genes and consequently deactivates protein translation, and since caffeine downregulates such aberration, the beneficial effect of caffeine could be attributed to its ability to suppress elevation of toxic miRs and consequent gene silencing.

MicroRNAs (miRNAs), noncoding and approximately 22 nt long ribonucleic acid molecules [1], control the functions of several genes under normal and diseased states [2]. MicroRNAs do so primarily by hybridization with nearly complementary base sequences in the 3′ untranslated regions of messenger RNAs (mRNAs) and consequently disabling them from performing their protein translational function [3]. Thus, mature microRNAs (miRs) function as important agents of gene silencing [4]. Since complete Watson and Crick complementarity is not required for hybridization of small nucleic acid molecules, the effect of miRs on gene silencing and subsequent physiologic effects could be more diverse than ordinarily expected [2]. In addition to the direct inhibitory effect on protein translation, such hybridization can also lead to destabilization of the mRNA itself and its eventual degradation. Physiologically, the resulting inhibition of protein translation is expected to be partial and total, depending upon the number of available miR molecules, as well as the number of available mRNA targets. In addition to targeting mRNAs, miRs have also been reported to hybridize with complementary sequences in the chromatin structure.

This can also cause gene silencing at the transcriptional level [5-7], limiting the transcription of mRNAs. Hybridization with mRNAs involved in the biogenesis of enzymes and cofactors involved in reactions causing methylation and acetylation [8-11] can also lead to generational and inter-generational epigenetic effects. Overexpression of miRs is therefore generally a toxic event, except in situations where the overexpression can be used to suppress the translational activity of mRNAs producing toxic proteins or enzymes, as is the case in certain cancers [12-14].

In addition to cancer, miR expression becomes deregulated in many other pathophysiological conditions, such as with the development of certain cardiac myopathies including cardiac hypertrophy and abnormalities in rhythmic amplitude and periodicity [15-17], neural malfunctions such as with Alzheimer disease and senile dementia [18,19], and diabetes [20,21]. Redox deregulation and consequent oxidative stress are cardinal features of most of these conditions, including diseases related to the loss of vision with aging and diabetes [22-27]. The high prevalence and severity of visual impairment in the diabetic population are strongly correlated with the degree of hyperglycemia [23]. This is evident form the delay in the development of vision loss achieved by controlling blood glucose levels toward normal levels [28]. That the high sugar level may play a significant role in visual
complications is also apparent from the development of cataracts in animals maintained on diets containing high amounts of other sugars such as galactose [29], arabinose [30], and xylose [31,32], in addition to diabetes [33-36]. Galactose has also been reported to cause abnormalities in retinal vasculature similar to that in diabetes [37,38]. However, information on the possible implications of aberrations in miR transcription and gene silencing induced by sugar-induced oxidative stress by high sugars remains limited. Such a possibility is strongly indicated by a recent report showing elevation in the transcription of several apoptotic miRs in the lenses of mice fed a high-galactose diet. That this elevation could be caused by oxidative stress was strongly indicated by the corrective effect of pyruvate, known to inhibit oxidative stress and cataract formation [39-42]. The increase in apoptotic miRs in galactosemic lenses was substantially attenuated in animals fed a diet mixed with pyruvate. Pyruvate also reverses oxidative stress—induced inhibition of glycolysis in the retina [43].

These studies on the possible enhancement of the transcription of toxic miRs caused by sugar-induced oxidative stress and its possible prevention by antioxidants have now been further examined using caffeine, a nutraceutical-derived compound known to act as a potent antioxidant [44,45] as well as inhibit apoptosis and cataract formation induced by a high-galactose diet [46,47]. We have now observed that the overexpression of most miRs noted in the galactosemic lens is significantly inhibited by adding caffeine to the diet. These findings could also be useful in explaining the lower incidence of cataracts in groups of persons consuming relatively higher levels of caffeine through coffee drinking (FAO drinks) [48,49].

METHODS

Materials: CD-1 mice were obtained from Harlan Lab Inc. (Indianapolis, IN). Reagents for RNA isolation, cDNA preparation, PCR amplification of the cDNAs, and the miRNA-finder array were obtained from SA Biosciences Corporation (Frederick, MD). Routine chemicals were obtained from Sigma-Aldrich (St. Louis, MO).

Methods: Mice weighing about 20 g were fed owered rodent chow (controls- Harlan Farm diet # 2018SX; Indianapolis, IN) or chow mixed with galactose to the 25% level or mixed with 25% galactose plus 1% caffeine. The dietary regimen was maintained for 7 days. The animals were labeled as A, B and C and fed concurrently with the respective diet. They were also scarified, and lens isolated at the same time to avoid any technical and diurnal variation. The numbers of animals in the individual groups were 2, 3 and 2 respectively, giving at least 4, 6 and 4 lenses in each group for analysis. The blood galactose level was 4±0.5 mm in both groups of galactosemic animals. The dietary regimens were maintained for only 7 days to minimize the extent of cataractous changes in the lens and consequent leakage of material. Subsequently, the animals were anesthetized with a ketamine/xylazine mixture (6 mg/100 g ketamine and 0.75 mg/100 g xylazine) and quickly euthanized by CO₂ inhalation. The eyes were then promptly enucleated and dissected to isolate intact lenses atraumatically. The isolated lenses were immediately frozen by immersion in liquid nitrogen and then immediately processed for miRNA-enriched RNA isolation using a Qiagen RNeasy reagent kit (cat no. 217,004; Valencia, CA), following the manufacturer’s protocol. Briefly, both lenses of each animal, each weighing about 8 mg individually, were homogenized in the lysis buffer containing phenol and guanidine thiocyanate. The lysate was then mixed with chloroform and centrifuged. The upper aqueous layer containing the RNAs was then aspirated, thoroughly mixed with 1.5 volumes of ethanol, and transferred quantitatively to an RNeasy mini-column attached to a 2 ml collection tube. After allowing a few minutes for equilibration and RNA binding, the column was spun, filtering out the reagents but retaining the RNA bound on the column. Extraneous material from the column was further removed by washing buffer. The column was then attached to a new collection tube, and RNA was finally eluted by adding RNase-free (50 µl) water to the column and centrifugation. Quantification of the RNA in the elute was then accomplished by measuring absorption at 260/280 nm. The ratio was always more than 1.8. The quality of the RNA was further ascertained electrophoretically. The concentration of RNA in the elute was 350 ng/µl. First strand cDNA synthesis was performed by mixing 1.5 µg (4.3 µl) of the RNA prep with an RT² First Strand cDNA Synthesis kit (SA Bioscences, Frederick, MD; MA-03/331401) reagent containing the primer and the reverse transcriptase in a total volume of 10 µl and incubating for 2 h at 37 °C. The tube was then heated for 5 min at 90 °C to inactivate the reverse transcriptase and chilled on ice; then the volume was increased to 100 µl. This was further diluted to 2,550 µl with 1,275 µl of 2X RT2 SYBR Green qPCR Master Mix (SA Bioscences) and 1,175 µl of water. Twenty-five µl of this mixture was then added to each well in the 96-well mi-Finder cassette (MAM 001), containing one universal primer and one gene-specific primer. PCR amplification was performed in an ABI 7900HT Real-Time PCR (Applied Biosystems, Foster City, CA) machine using the three-step cycling program. The resulting threshold cycle (Ct) data for all wells was then transferred to an Excel spreadsheet and exported to Support@SABiosciences.com for further analysis.
RESULTS

As reported previously, using an RT²-PCR protocol based on first strand cDNA synthesis by reverse transcriptase reaction followed by quantification of the cDNA by PCR, using the microRNA finder cassette containing the primers corresponding to cDNAs, the presence of all 84 miR species reported to be present in most samples analyzed can be detected (cat no. MAM-001; SA Bioscience). The objective of the present study was to ascertain if incorporating caffeine in a galactose diet has an effect on the miR transcription level. Table 1 summarizes the miR expression levels obtained in the lenses of mice fed a normal diet (Group A), a galactose diet (Group B), and a galactose+caffeine diet C, the expression levels expressed as \(2^{(-\Delta Ct)}\), and the relative fold (regulation) values. As is apparent by the fold values labeled B/A (the ratio of expression between galactosemic and normal lenses), galactose feeding leads to a substantial elevation in the transcription of at least 19 miRs, the fold value at least more than 2. A similar elevation in most of these miRs has been previously reported [39]. These miRs have been widely reported to be largely proapoptotic. However, the transcription of at least three miRs was intriguingly repressed, suggesting the possibility of a protective tissue response, moderating the extent of tissue damage.

| Name          | Group A Normal | Group B Galactose | Group CGal+Caffeine | Fold values (C/A) | Fold values (C/B) | Fold values (B/A) |
|---------------|----------------|-------------------|--------------------|-------------------|-------------------|-------------------|
| mmu-miR-32   | 0.206379       | 0.028751          | 0.048312           | −4.27             | 1.68              | −7.18             |
| mmu-miR-503  | 0.215076       | 0.501             | 0.932804           | 4.34              | 1.86              | 2.33              |
| mmu-miR-199a-5p | 0.005404     | 0.001846          | 0.003261           | −1.66             | 1.77              | −2.93             |
| mmu-miR-138  | 0.021333       | 0.036355          | 1.70               |                   |                   |                   |
| mmu-miR-142–5p | 0.0012        | 0.000807          | 0.000469           | −2.56             | −1.72             | −1.49             |
| mmu-miR-16   | 4.494815       | 35.633964         | 18.978262          | 4.22              | −1.88             | 9.73              |
| mmu-miR-124  | 2.653982       | 1.346003          | 1.97               |                   |                   | 1.83              |
| mmu-miR-126–3p | 0.337068      | 2.86875           | 1.129979           | 3.35              | −2.54             | 8.51              |
| mmu-miR-9    | 0.132899       | 1.892583          | 0.666452           | 5.01              | −2.84             | 14.24             |
| mmu-miR-27a  | 8.5713         | 5.320316          |                   | −1.61             | 2.14              |                   |
| mmu-miR-155  | 0.002994       | 0.001531          | −1.96              | 2.58              |                   |                   |
| mmu-miR-872  | 0.51421        | 3.31476           | 2.061161           | 4.01              | −1.61             | 6.45              |
| mmu-miR-126–5p | 0.155496      | 2.671638          | 1.323574           | 8.51              | −2.02             | 17.18             |
| mmu-miR-196b | 0.00005        | 0.000807          | 0.000418           | 8.36              | −1.93             | 16.14             |
| mmu-miR-196a | 0.0003         | 0.002178          | 0.001035           | 3.45              | −2.10             | 7.26              |
| mmu-miR-30c  | 7.572804       | 34.429444         | 22.789992          | 3.01              | −1.51             | 4.55              |
| mmu-miR-880  | 0.000425       | 0.001157          | 0.000675           | 1.59              | −1.71             | 2.72              |
| mmu-miR-182  | 0.046855       | 0.143981          | 0.074427           | 1.59              | −1.93             | 3.07              |
| mmu-miR-411  | 0.013525       | 0.074768          | 0.04618            | 3.41              | −1.62             | 5.53              |
| mmu-miR-125b-3p | 0.002612     | 0.001555          | −1.68              | 2.08              |                   |                   |
| mmu-miR-295  | 0.000097       | 0.000807          | 0.000239           | 2.46              | −3.38             | 8.32              |
| mmu-miR-218  | 4.638208       | 33.580832         | 23.433166          | 5.05              | −1.43             | 7.24              |
| mmu-miR-335–5p | 0.032472      | 1.255721          | 0.240619           | 7.41              | −5.22             | 38.67             |
| mmu-miR-101a | 0.549524       | 0.444408          | 0.215054           | −2.56             | −2.07             |                   |
| mmu-miR-141  | 0.003004       | 0.001621          | 0.000889           | −3.38             | −1.82             | −1.85             |
| mmu-miR-374  | 0.845519       | 8.645346          | 5.530468           | 6.54              | −1.56             | 10.22             |

The values in the table represent means of 4 lenses in groups A, 6 lenses in group B and 4 lenses in group C. The numbers represent the gene expression levels as \(2^{(-\Delta Ct)}\), normalized with respect to the reagent controls as well as the house keeping gene. The fold changes are ratios of the expression levels.
diet. Adding caffeine to the galactose diet significantly annulled the miR elevation caused by galactose. The galactose+caffeine/normal ratios were significantly lower than the fold values for the galactose without caffeine/normal. This conforms to our earlier observation showing that caffeine inhibits galactose-induced apoptosis, while inhibiting the formation of cataracts [46].

MiR expression in the galactose plus caffeine group was compared with that in the galactose alone group under C/B. The relative expression levels of the miRs in the galactose+caffeine group were strikingly lower compared to those in the galactose alone group; the ratios were negative. The results therefore strongly suggest that caffeine inhibits the transcription of toxic miRs, as indicated by the C/B ratios.

**DISCUSSION**

The intake of caffeine, derived either through a beverage or as a drug, is followed by several normal physiologic effects, such as stimulating the nervous, cardiovascular, and musculoskeletal systems, relaxing the bronchial and vascular smooth muscles, and promoting diuresis, intestinal motility, etc [50-56]. The stimulation of the nervous system is reflected by enhanced alertness, mental hyperactivity, arousal, wakefulness, enhanced cognitive ability, tolerance of pain, and ergonomic improvements. These neural effects are attributed largely to the competitive binding of caffeine to adenosine receptors on the presynaptic nerve terminals, as the structure of caffeine is similar to adenosine. Since the occupation of these receptors by adenosine limits the amount of calcium translocation to inside the cells through the voltage-gated and voltage-independent calcium channels, their blockade by caffeine minimizes such limitation, and thus increases cytosolic calcium levels [57,58]. The increase in cellular calcium in turn facilitates vesiculation of the neurotransmitters and their release in the synaptic cleft. The release of these neurotransmitters including acetylcholine, norepinephrine, dopamine, and some others [59-61] is thus responsible for enhancing neural transduction and stimulating the cardiac pacemaker cells [62,63]. The cardiovascular stimulation reflected by enhanced contractibility of the cardiac muscle has also been shown to the effect of opening the calcium channels in the sarcoplasmic reticulum of the cardiac myocytes, releasing the sequestered Ca$^{2+}$ into the cytosol. The increased cytosolic Ca$^{2+}$ in turn stimulates muscle contraction via interaction with the actomyosin complex. The vasodilatory effect of Ca$^{2+}$ is exerted through activation of nitric oxide synthase, resulting in increased nitric oxide and cyclic guanosine monophosphate levels. Therefore, most of the acute effects of caffeine are exerted through its action of increasing the intracellular levels of free calcium. In addition, caffeine inhibits cyclic adenosine monophosphate phosphodiesterase, increasing the adenosine triphosphate levels [64]. Although this phenomenon is used by athletes to improve their physical performance, such elevation requires much higher amounts of caffeine than ordinarily possible. Hence, the action of caffeine through the latter effect is normally less significant.

However, in addition to these transient effects, which are largely obliterated in regular coffee drinkers, several recent reports have emphasized many long-term beneficial effects of caffeine consumption, such as caffeine’s effect against the development of age-related dementia and cognitive loss [65-67], as well as Alzheimer disease [68,69]. The latter effect is ascribed to inhibition of the formation and accumulation of beta-amyloid plaques and fibrils in the brain due to enhanced cleavage of the parent transmembrane amyloid precursor protein [70-73]. Caffeine has also been found to be beneficial against Parkinson disease [74,75]. This is linked to caffeine’s preventive effect against oxidative damage to the cells in the pars compacta of the substantia nigra [76-78] and consequent imbalance in the production and release of dopamine and acetylcholine that causes dyskinesia. Caffeine consumption has also been shown to be related to attenuation of liver cirrhosis [79,80] and the development of certain cancers [81,82].

Interestingly, caffeine has a highly significant effect of decreasing the risk of the development of type 2 diabetes [83-85], a highly prevalent aging disease whose incidence is projected to undergo a substantial increase in the coming years [86]. Additionally, age- and diabetes-associated mortality has also been found to be inversely correlated with coffee consumption; mortality is significantly lower in groups consuming higher amounts of coffee per day [87-89]. The mechanism of such protective effects of caffeine could be diversified. The possibility that caffeine could also be related to its continued diuretic effect and consequent excretion of the toxicants produced by oxidative stress, including those produced by oxidation of sugars, and of the sugars themselves, remains to be elucidated. Since caffeine is a potent antioxidant, we propose that in addition to acting as general antioxidant, caffeine also inhibits oxidative stress—induced aberrations in microRNA transcription. Therefore, caffeine can potentially protect tissue against miRNA-induced silencing of important antioxidant genes. This effect of inhibiting oxidation-induced gene silencing likely provides additional antioxidant advantage compared to most other antioxidants such as superoxide dismutase, catalase, and other peroxide decomposing enzymes that remain essentially
restricted in the extranuclear compartment of the cell. Most redox active soluble compounds present in cells are also unstable and rapidly catabolized [90]. Caffeine, however, is much more stable and well distributed following its intake. The present findings showing caffeine’s inhibitory effect against oxidative stress–induced elevation of toxic miRs is hence considered pathophysiologically useful. The findings also suggest that the inhibitory effect of caffeine against apoptosis that precedes sugar cataract formation as reported earlier [46] is due to inhibition of the biogenesis of proapoptotic miRs. Although caffeine’s effect of preventing oxidative stress and biogenesis of toxic miRs has so far been shown in hyper-galactosemic conditions, we speculate caffeine has similar effects against the effects of high glucose that persist in diabetic conditions. The elevation of microRNAs, in addition to causing gene silencing at the level of mRNAs involved in the biogenesis of antioxidant enzymes, could also exert a detrimental effect by inhibiting certain upstream pathways such as the nuclear factor (erythroid-derived 2)-like 2/Kelch-like ECH-associated protein 1 pathway [91,92] involved in the transcription of antioxidant genes. Further studies on the mode of caffeine effects are thus in progress.

According the U.S. Food and Drug Administration, caffeine, one of the most common nutraceuticals, is highly safe for human use. Caffeine’s median lethal dose (LD50) is estimated to be at least greater than 10 g, with lethality unknown. In experimental animals, the LD50 is high: 355 mg/kg (Merck Index) in rats, equivalent to about 25 g/70 kg in humans. The effective anticataract dose of caffeine in galactosemic rats is 15 mg/kg/day [46], which is only about 4% of the LD50. No toxicity, systemic or ocular, was observed. Additionally, several multivariate analyses identifying the nutritional risk factors for cataracts have also found caffeine to be safe. Indeed, as summarized before, the global incidence of cataracts [48] also appears to be negatively correlated with caffeine intake, being markedly lower in countries with higher intake (≥200 mg per day) than in countries with lower intake such as China and India and in Central and South America [49]. Contrary to some early suggestions [93] that caffeine could have an adverse effect of increasing intraocular pressure, substantially large epidemiological and clinical studies [94-97] have disproved this. A transient rise of 1–2 mmHg sometimes noted following a coffee drink is in fact attributable to the hemodynamic effect due to water content associated with the drink [98-101], water intake being a standard test for glaucoma. Therefore, the possibility of any significant toxic effect of caffeine to eye is highly remote. The results showing its effectiveness against the transcription of several pro apoptotic microRNAs, coupled with its inhibitory effect against actual cataract formation in vivo strongly suggests its possible pharmacological use in cataract prevention. The inhibitory effect of this compound against toxic miRNA transcription has been shown for the first time.

REFERENCES

1. Lee RC, Fein Baum RL, Ambros V, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-54. [PMID: 8252621].

2. Bartel DP. Micro RNAs: Target recognition and regulatory functions. Cell 2009; 136:215-33. [PMID: 19167326].

3. Lim LP, Nelson CL, Garrett-Engel P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows that some microRNAs down regulate large number of target mRNAs. Nature 2005; 433:769-73. [PMID: 1565193].

4. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007; 8:23-6. [PMID: 17183358].

5. Bentwich I, Avniel A, Karv Y, Aharnoo R, Giald S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E. Spector, Bentwich z. Identification of hundreds of conserved and non-conserved human microRNAs. Nat Genet 2005; 37:766-70. [PMID: 15965474].

6. Lewis BP, Burge CB, Bartles DP. Conserved seed pairing, often flanked by adenosine, indicates that thousands of human genes are micro RNA targets. Cell 2005; 120:15-20. [PMID: 15652477].

7. Tan Y, Zhang B, Wu T, Wu T, Skogerbo G, Zhu X, Guo X, He S. Chen, R. Transcriptional inhibition of Hoxd4 expression by noncoding RNAs in human breast cancer cells. BMC Mol Biol 2009; 10:12-21. [PMID: 19232136].

8. Hawkins PG. Morris KV. RNA and transcriptional modulation of gene expression. Cell Cycle 2008; 7:602-7. [PMID: 18256543].

9. Morozova N, Zinovyev A, Nonne N, Pritchard LL, Gorban AN, Harel-Bellan A. Kinetic signatures of microRNA modes of action. RNA 2012; 18:1635-55. [PMID: 22850425].

10. Fumiaki S, Soken T, Stephen J. M, Shumaizu K. Micro RNAs and epigenetics. A Mmini Review. FEBS J 2011; 278:1998-1609. .

11. Chuang JC, Jones PA. Epigenetics and MicroRNAs. Pediatr Res 2007; 61:24R-9R. [PMID: 17413852].

12. Mraz M, Pospisilova S, Malinova K. MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 2009; 50:506-9. [PMID: 19347736].

13. Lu J, Getz G, Miska EA, Alvarez-Salvedra E, Lamb J. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8. [PMID: 15944708].

14. Nielsen BS, Jorgensen S, Gog JU, Sokilde R, Christensen IJ, Hansen U. Brunner, Basar A, Moller S, Nielsen JJ, High levels of micro RNA-21 in the stroma of colorectal cancers
predict short disease free survival in state II colon cancer patients. Clin Exp Metastasis 2011; 28:27-38. [PMID: 21069438].

15. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, Meissner G, Patterson C, Hannon GJ, Wang DZ. Targeted deletion of dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 2008; 105:2111-6. [PMID: 18256189].

16. van Rooij E, Sutherland LB, Liu N, Williams AH, McNally J, Gerard RD, Richardson RA, Olson EN. A signature pattern of stress responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103:18255-60. [PMID: 17108080].

17. Tatsuguchi M, Seok HY, Callis TE, Thomson J. M, Chen JF, Newman M, Rojas M, Hammond SM, Wang Da-Zhi. Expression of microRNA is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007; 42:1137-41. [PMID: 17498736].

18. Maes OC, Chertkow HM, Wang E, Schipper HM. MicroRNA: Implications for Alzheimer disease and other human CNS disorders. Curr Genomics 2009; 10:154-68. [PMID: 19881909].

19. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 2010; 15:1176-9. [PMID: 19721432].

20. Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang N, Zhang Y, Yang B, Wang Z. MicroRNA miR-133 suppresses K+ Channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 2011; 286:12363-7. [PMID: 21919169].

21. Tang X, Tang G, Ozcan S. Role of microRNA in diabetes. Biochim Biophys Acta 2008; 9:697-701. [PMID: 17498736].

22. Harding JJ, Egerton M, van Heyningen R, Harding RS. Diabetes, glaucoma, sex, and cataract: analysis of combined data from two case control studies. Br J Ophthalmol 1993; 77:2-6. [PMID: 8435392].

23. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR. The Framingham eye study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham heart study. Am J Epidemiol 1977; 106:33-41. [PMID: 141882].

24. Tabin G, Chen M, Espandar L. Cataract surgery for the developing world. Curr Opin Ophthalmol 2008; 19:55-9. [PMID: 18090899].

25. Klein BE, Klein R, Moss SE. Incidence of cataract surgery in the Wisconsin. Epidemiologic Study of Diabetic Retinopathy. Am J Ophthalmol 1995; 119:295-300. [PMID: 7872389].

26. Klein BE, Klein R, Wang Q, Moss SE. Older-onset of diabetes and lens opacities. The Beaver Dam Eye Study. Ophthalmic Epidemiol 1995; 2:49-55. [PMID: 7585233].

27. Klein BE, Klein R, Moss MS. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. Ophthalmology 1985; 92:1191-6. [PMID: 4058882].

28. The diabetes control and complications trials research group. Diabetes 1995; 44:968-83. [PMID: 7622004].

29. Mitchel HS, Dodge WM. Cataracts in rats fed high galactose rations. J Nutr 1935; 9:37-49. [PMID: 11473058].

30. Keller HW, Koch HR, Ohrloff C. Experimental arabinose cataracts in young rats. Ophthalmic Res 1977; 9:205-12. [PMID: 7622004].

31. Patterson JW. Cataractogenic Sugars. Arch Biochem 1955; 58:24-30. [PMID: 13259673].

32. Van Heyningen R. Metabolism of Xylose in the Lens. Biochem J 1959; 73:197-207. [PMID: 13841079].

33. Varma SD, Mikuni I, Kinoshita JH. Flavonoids as inhibitors of lens aldose reductase. Science 1975; 188:1215-6. [PMID: 1145193].

34. Varma SD, Kinoshita JH. Inhibition of aldose reductase by flavonoids. Their possible role in the prevention of diabetic cataracts. Biochem Pharmacol 1976; 25:2505-13. [PMID: 825129].

35. Varma SD, Mizuno, A. and Kinoshita, J.H. Diabetic cataracts and flavonoids Science 1977; 195:205-6. [PMID: 401544].

36. Kador PF, Akagi Y, Kinoshita JH. The effect of aldose reductase and its inhibition on sugar cataract formation. Metabolism 1986; 35:15-9. [PMID: 3083204].

37. Kador PF, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita JH. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1990; 108:1301-9. [PMID: 21919169].

38. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental Galactosemia, VII. Effect of Long-Term Administration of Antioxidants on the Development of Retinopathy. Diabetes 2001; 50:1938-42. [PMID: 11473058].

39. Varma SD, Kovtun S, Hegde KR, Yin J, Ramnath J. Effect of high sugar on miRNA expression. Studies with galactosemic mice lens. Mol Vis 2012; 18:1609-18. [PMID: 22736950].

40. Varma SD, Morris S. Peroxide damage to the eye lens in vitro prevention by pyruvate. Free Rad Res Common 1988; 4:283-90. [PMID: 3234857].

41. Hegde K, Kovtun S, Varma SD. Prevention of cataract in diabetic mice by topical pyruvate. Clinical Ophthalmology 2011; 5:1141-5. [PMID: 21887096].

42. Varma SD, Devamanoharan PS, Rutzen AR, Ali AH, Henein M. Attenuation of galactose induced cataract by pyruvate. Free Rad Res 1988; 20:141882. [PMID: 21887096].

43. Varma SD, Devamanoharan PS, Rutzen AR, Ali AH, Henein M. Attenuation of galactose induced cataract by pyruvate. Free Rad Res 1988; 20:141882. [PMID: 21887096].

44. Shi X, Dalal NS, Jain AC. Antioxidant behavior of caffeine: efficient scavenging of hydroxyl radicals. Food Chem Toxicol 1991; 29:1-6. [PMID: 1847890].

45. Stadler RH, Fay LB. Antioxidative reactions of caffeine. Formation of 8-oxo-caffeine (1,3,7trimethyl uric acid) in
coffee subjected to oxidative stress. J Agric. Food em. 1995; 43:13321338.

46. Varma SD, Hegde KR, Koytun S. Effectiveness of topical caffeine in cataract prevention. Studies with galactose cataract. Mol Vis 2010; 16:2626-33. [PMID: 21179241].

47. Varma SD, Hegde KR. Kynurenine induced photo oxidative damage in lens in vitro: Protective effect of caffeine. Mol Cell Biochem 2010; 340:49-54. [PMID: 20204679].

48. Resnikoff S, Pascoline D, Etyaale KI, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ 2008; 86:63-70. [PMID: 18235892].

49. Gilbert RM. Caffeine consumption. Prog Clin Biol Res 1984; 158:185-213. [PMID: 6396645].

50. Serafin WE. In: Hardman JG Limbered LE, Molino PB, Ruddon RW, In Goodman & Gillman’s Pharmacological basis of therapeutics. 9th edition. New York: McGraw Hill; 1996; p. 673–79.

51. Arnaud MJ. The pharmacology of caffeine. Prog Drug Res 1987; 38:273-313. [PMID: 3326033].

52. Wilson DF. Effect of caffeine on neuromuscular transmission in rat. Am J Physiol 1973; 225:862-5. [PMID: 4355178].

53. Dunwiddie TV. Interaction between the effects of adenosine and calcium in synaptic responses in rat hippocampus in vitro. J Physiol 1984; 350:545-59. [PMID: 6086898].

54. Goldstein A, Kaizers S, Warren R. Psychotropic effects of caffeine in man II. Alertness, psychomotor coordination, and mood. J Pharmacol Exp Ther 1965; 150:146-51. [PMID: 5853694].

55. Rousseau E, Ladine J, Liu QY, Meissner G. Activation of the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum by caffeine and related compounds. Arch Biochem Biophys 1988; 267:75-86. [PMID: 2848455].

56. Batting K. The physiological effects of coffee consumption. In: Coffee: Botany, Biochemistry and production of beans and beverage. Ed. MM Clifford and KC Wilson. Publisher: Crown-Helm, London, P 394–439, 1985.

57. Daly JW, Burns RF, Snyder SH. Adenosine receptor in the central nervous system: Relationship to the central actions of methylxanthines. Life Sci 1981; 12:2083-97. [PMID: 6114369].

58. Pedata F, Giovanelli L, De Samo P, Pepeu B. Effect of adenosine derivatives and caffeine on acetylcholine release from the brain synaptosomes: Interaction with muscarinic regulatory mechanisms. J Neurosci 2002; 22:6321-4. [PMID: 12151508].

59. Solinas M, Ferre S, You ZB, Karcez-Kubicha M. Popoli, Goldberg SR. Caffeine induced dopamine and glutamate release in the shell of nucleus accumbens. J Neurosci 2002; 22:6321-4. [PMID: 12151508].

60. Morgan ME, Vestal RE. Methylxanthine effects on caudate dopamine release as measured by in vivo electrochemistry. Life Sci 1989; 45:2025-39. [PMID: 2601563].

61. Degubareff T, Sleator W Jr. Effects of caffiene on the mammalian atrial muscle and interaction with adenosine and calcium. J Pharmacol Exp Ther 1965; 148:202-14. [PMID: 14301011].

62. Blinks JR, Olson CB, Jewell BR, Braverney P. Influence of caffeine and other methyl xanthines on the mechanical properties of isolated mammalian heart muscle. Circ Res 1972; 30:367-92. [PMID: 4401230].

63. Dobmeyer DJ, Eer RA, Greenberg R, Schaal SF. The arrhythmogenic effects of caffeine in man. N Engl J Med 1983; 308:814-6. [PMID: 6835272].

64. Beavo JA, Rogers NL, Crawford OB, Hardman JG, Sutherland WW, Newman EV. Effect of xanthine derivatives on lipolysis and on adenosine 3’,5’-monophosphate phosphodiesterase activity. Mol Pharmacol 1970; 6:597-603. [PMID: 4322367].

65. Ritchie K, Carriere I, De Mendoça A, Portet F, Dartigues JF, Rouaud JF. O Barberger-Gateau, Ancelin ML. The neuroprotective effects of caffeine. Neurology 2002; 69:536-45. .

66. Corley J, Jia X, Kyle Janet AM, Gow AJ, Brett CE, Starr JM, McNeill GM, Deary IJ. Caffeine consumption and cognitive function at age 70: The Lothian birth cohort 1936 study. Psychosom Med 2010; 72:206-14. [PMID: 19995882].

67. Jarvis MJ. Does caffeine intake enhance absolute levels of cognitive performance. Psychopharmacology (Berl) 1993; 110:45-52. [PMID: 7870897].

68. Johnson-Kozlow M, Silversteine DK, Connor EB, Morton D. Coffee and cognitive function in older adults. Am J Epidemiol 2002; 156:842-50. [PMID: 12397002].

69. Lindsay J, Laurin D, Verreault R, Herbert R, Hellwell B, Hill GB, McDowell I. Risk Factors for Alzheimer’s disease: A Prospective Analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002; 156:445-53. [PMID: 12196314].

70. Maia L, de Mendoça A. Does caffeine intake protect from Alzheimer’s disease? Eur J Neurol 2002; 9:377-82. [PMID: 12099922].

71. Hardy J, Allisop D. Amyloid deposition as the central event in the etioloogy of Alzheimer’s disease. Trends Pharmacol Sci 1991; 12:383-8. [PMID: 1763432].

72. Wenk GL. Neuropathologic changes in Alzheimer’s disease. J Clin Psychiatry 2003; 64:7-10. [PMID: 12934968].

73. Turner PR, O’Connor K, Tate WP, Abraham W.C. Role of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 2003; 70:1-32. [PMID: 12927332].

74. Shen ZX. Brain cholinesterase. The molecular and cellular basis of Alzheimer’s disease. Med Hypotheses 2004; 63:308-21. [PMID: 15236795].

75. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchelette PL, Curb JD, Popper JS, White LR. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283:2674-9. [PMID: 10819950].
76. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlkogke J, Schiad DJ, Rocca WA. Smoking, alcohol, and coffee consumption preceding Parkinson’s disease. Neurology 2000; 55:1350-8. [PMID: 11087780].
77. Olanow CW, Tatton WG. Etiology and Pathogenesis of Parkinson’s disease. Annu Rev Neurosci 1999; 22:123-44. [PMID: 10202534].
78. Dawson TM, Dawson V. Molecular pathways of neurodegeneration in Parkinson’s disease Science 2003; 302:819-22. [PMID: 14593166].
79. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006; 166:1190-5. [PMID: 16772246].
80. Corrao G, Zamboni A, Bagnardi V, D’Amico’s A, Klatsky A. Coffee, caffeine and the risk of liver cirrhosis. Ann Epidemiol 2001; 11:458-65. [PMID: 11557177].
81. Shiraz T, Tesbin Y, Koriyama S. Coffee consumption and the risk of primary liver cancer. Pooled analysis of two prospective studies in Japan. Int J Cancer 2005; 97:293-300.
82. Camden IS, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. Aliment. Pharmacol. 2007; 26:1-819.
83. Salazar-Martinez E, Willett WC, Ascherio A, Manson JE, Leitzmann MF, Stampfer MJ, Hu FB. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med 2004; 140:1-8. [PMID: 14706966].
84. Huxley R, Lee CM, Barzi F, Timmermeister L, Czernichow S, Perkovic V, Grobbee DE, Batty D, Woodward M. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus Arch Intern Med 2009; 169:2053-63. [PMID: 20008687].
85. Hu G, Joussilait P, Peltonen M, Bidet S, Tuormilehto J. Joint association of coffee consumption and other factors to the risk of type 2 diabetes: a prospective study in Finland. Obesity (London) 2006; 30:1742-9. [PMID: 16652136].
86. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-53. [PMID: 15111519].
87. Lopez-Garcia E, van Dam RM, Li TY, Rodriguez-Artalejo F, Hu FB. The relationship of coffee consumption with total and cause specific mortality. N Engl J Med 2010; 366:1891-904.
88. Neal D, Freedman, Yikyung Park, Christian C. Abnet, Albert R. Hollenbeck, Sinha R. Association of coffee dinking with articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. The print version of this article was created on 25 February 2013. This reflects all typographical corrections and errata to the article through that date. Details of any changes may be found in the online version of the article.